塞力醫療(603716.SH):旗下聯營企業華紀元生物是公司投資的參股公司,持有其15.61%股份
格隆匯7月10日丨塞力醫療(603716.SH)公佈股票交易異常波動公告,公司關注到近期市場對創新藥業務關注度較高。公司旗下聯營企業武漢華紀元生物技術開發有限公司(簡稱“華紀元生物”)是公司於2020年1月投資的參股公司,持有其15.61%的股份,投資金額1,066.6萬元,華紀元生物2024年營業收入2.68萬元,淨利潤-238.23萬元。其治療性降壓疫苗項目HJY-ATRQβ-001已完成概念驗證(POC)階段研究和臨牀前研究,已於2025年6月6日獲得國家藥監局(NMPA)的新藥臨牀試驗申請(IND)受理,後續還需經一期、二期臨牀試驗,試驗能否成功還存在重大不確定性。上述投資目前對公司主營業務的影響較小,敬請投資者注意相關風險,理性決策,審慎投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.